Relypsa, Inc., a pharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. The company’s principal product candidate includes Patiromer, a non-absorbed potassium binder that completed Phase 3 clinical trial for the treatment of hyperkalemia. It also offers RLY6002, a pre-clinical product candidate that evaluates as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus. The company was founded in 2007 and is headquartered in Redwood City, California.
700 Saginaw Drive
Redwood City, CA 94063
Founded in 2007
Relypsa Reports Manufacturing Agreement for Blood Drug
Sep 9 14
Relypsa announced a multi-year agreement with Patheon, Inc. to manufacture of patiromer, RLYP's hyperkalemia drug. Hyperkalemia refers to elevated levels of potassium in the blood, often resulting from chronic kidney disease, hypertension, diabetes and/or heart failure. Hyperkalemia can lead to life-threatening cardiac arrhythmia and sudden death.
Relypsa, Inc. Announces Data from its Pivotal Phase 3 Clinical Trial of Patiromer
Sep 8 14
Relypsa, Inc. announced that data from its pivotal Phase 3 clinical trial of patiromer will be presented as a late-breaking oral presentation at the 18(th) Annual Scientific Meeting for the Heart Failure Society of America (HFSA) to be held in Las Vegas during September 14-17, 2014. The data will be presented at HFSA by Bertram Pitt, M.D., professor of Medicine, Emeritus, University of Michigan School of Medicine. An analysis of the data will be presented that assesses the ability of patiromer to reduce elevated serum potassium (serum K(+)). Following the achievement of normal potassium levels, the study then evaluated whether continued treatment with patiromer would maintain control of serum K(+) and reduce the recurrence of hyperkalemia compared to placebo. The analysis was conducted in heart failure (HF) patients with chronic kidney disease (CKD) and mild to severe hyperkalemia who were also receiving renin angiotensin aldosterone system (RAAS) inhibitor therapy. In addition to presenting placebo-controlled comparative data on the recurrence of hyperkalemia after having controlled serum potassium levels, the presentation will include findings on whether HF patients in the study were able to remain on guideline-recommended RAAS inhibitor therapy.
Relypsa, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revised Financial Guidance for the Full Year 2014
Aug 11 14
Relypsa, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations was $16,397,000, net loss of $16,737,000 or $0.51 per basic and diluted share against loss from operations was $16,283,000, net loss of $20,220,000 or $64.87 per basic and diluted share a year ago.
For the six months, the company reported loss from operations was $32,101,000, net loss of $32,805,000 or $1.04 per basic and diluted share against loss from operations was $41,422,000, net loss of $46,471,000 or $149.42 per basic and diluted share a year ago.
With respect to financial expectations for the full year 2014, the company is narrowing its operating expense guidance to a range of $75.0 to $85.0 million, including $5.0 to $10.0 million in stock-based compensation, from a range of $75.0 to $95.0 million. The 2014 operating expenses will be primarily driven by ongoing development activities and expansion of commercial launch preparation activities related to patiromer and increases in the company's general and administrative infrastructure.